|
|
||||||||
J Thorac Cardiovasc Surg 1996;112:1307-1314
© 1996 Mosby, Inc.
CARDIAC AND PULMONARY REPLACEMENT |
Supported by National Institutes of Health grant 12 R01 HL41281 and a grant from Chugai Pharmaceutical Co., Ltd.
Received for publication May 6, 1996 Revisions requested May 20, 1996; revisions received June 12, 1996 accepted for publication June 13, 1996. Address for reprints: G. Alexander Patterson, MD, Division of Cardiothoracic Surgery, Wahington University School of Medicine, 3108 Queeny Tower, One Barnes Hospital Plaza, St. Louis, MO 63110
Abstract
Background: Lung allograft ischemia-reperfusion injury, characterized by increased pulmonary vascular resistance, pulmonary edema, and hypoxia, is the most frequent cause of early graft failure. Exogenous nitric oxide has been shown to reduce lung allograft reperfusion injury. During hypoxia, the adenosine triphosphatesensitive potassium channel is an important ionic channel that links the bioenergetic metabolism to membrane excitability. It has been shown to play a critical role in vascular permeability and in activation of neutrophils and their subsequent interaction with vessel wall cellular components. The purpose of this study was to investigate whether nicorandil, a novel nitric oxide generator and adenosine triphosphatesensitive potassium-channel opener, might enhance lung preservation and prevent allograft reperfusion injury. Materials and methods: Fourteen dogs underwent left lung allotransplantation. Donor lungs were flushed with modified Euro-Collins solution and stored for 21 hours at 1° C. Immediately after transplantation, the contralateral right main pulmonary artery and bronchus were ligated to assess isolated allograft function. Hemodynamics and arterial blood gas analysis (inspired oxygen fraction 1.0) were assessed for 6 hours before the dogs were put to death. After the assessment, activity of allograft myeloperoxidase and protein levels of bronchoalveolar lavage fluid were measured. Control animals (group I, n = 5) received no nicorandil. In group II (n = 5), the donor lung received nicorandil (24 mg/L) in the flush solution. In addition, recipient animals received nicorandil (0.5 mg/kg, intravenously) just before reperfusion, as well as a continuous infusion (0.74 ± 0.03 mg/kg per hour) during the 6-hour assessment period. In group III (n = 4), glibenclamide, a selective adenosine triphosphatesensitive potassium-channel blocker, was administered 15 minutes before nicorandil administration to both donor and recipient. The animals in group III received nicorandil in the same regimen as group II. Result: Superior gas exchange and hemodynamics were observed in lungs receiving only nicorandil. Allograft myeloperoxidase activity and protein levels in bronchoalveolar lavage fluid were significantly reduced in group II. Glibenclamide eliminated the beneficial effects of nicorandil. Conclusions: Nicorandil administration in the flush solution and during the reperfusion period ameliorates lung allograft dysfunction, improves blood flow, and reduces pulmonary vascular resistance and myeloperoxidase activity in the transplanted lung. The present study suggests that nicorandil reduces lung allograft reperfusion injury. The beneficial effects of nicorandil may be attributed to its properties as an adenosine triphosphatesensitive potassium-channel opener. (J THORAC CARDIOVASC SURG 1996;112:1307-14)
This article has been cited by other articles:
![]() |
C. Leroy, A. Dagenais, Y. Berthiaume, and E. Brochiero Molecular identity and function in transepithelial transport of KATP channels in alveolar epithelial cells Am J Physiol Lung Cell Mol Physiol, May 1, 2004; 286(5): L1027 - L1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fukuse, T. Hirata, M. Omasa, and H. Wada Effect of Adenosine Triphosphate-Sensitive Potassium Channel Openers on Lung Preservation Am. J. Respir. Crit. Care Med., June 1, 2002; 165(11): 1511 - 1515. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Suda, B. N. Mora, F. D’Ovidio, J. A. Cooper, M. Hiratsuka, W. Zhang, T. Mohanakumar, and G. A. Patterson IN VIVO ADENOVIRUS-MEDIATED ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE TRANSFER AMELIORATES LUNG ALLOGRAFT ISCHEMIA-REPERFUSION INJURY J. Thorac. Cardiovasc. Surg., February 1, 2000; 119(2): 297 - 304. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |